COMPARISON OF CORONARY ARTERY GRAFT PATENCY USING ANGIOGRAPHY AND 64-SLICE CT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：本研究的目的是比较多层螺旋CT(MSCT)和冠状动脉造影术(CA)评价冠状动脉旁路移植术(CABG)通畅性的准确性，这些患者术后一年已在圣安东尼奥VA医院参加CSP517研究。 研究计划和方法：这是一项前瞻性的对比研究，研究对象是先前参加过VA合作研究的AMVAH患者，该研究题为“心肌血管重建后的结果：开启和关闭体外循环”(CSP 517)，这些患者已经完成了CSP 517方案，接受了为期一年的冠状动脉造影术，并且没有MSCT的禁忌症。CSP517研究中不符合排除标准的患者将被邀请参加这项初步研究，主要目标是在接受为期一年的随访CA后两个月内完成切片MSCT。 临床意义：本研究将确定与“金标准”冠状动脉搭桥术相比，层螺旋CT能否以更低的风险和更低的成本为无症状的冠状动脉搭桥术后患者提供同等的移植物再通信息。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: The objective of this study is to determine the accuracy of 64-slice Multislice Spiral Computer Tomography (MSCT) when compared to Coronary Angiography (CA) for evaluation of Coronary Artery Bypass Graft (CABG) patency, in asymptomatic patients one year after surgery, already enrolled in the CSP 517 study at the San Antonio VA Hospital (AMVAH). RESEARCH PLAN AND METHODS: This is a comparative, prospective study with AMVAH patients previously enrolled in the VA Cooperative Study entitled "Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass" (CSP 517) who have completed their participation in the CSP 517 protocol, have had their one-year coronary angiogram, and do not have a contraindication to MSCT. Patients from the CSP 517 study who do not meet exclusion criteria will be invited to participate in this pilot study with the primary objective of completing a 64-slice MSCT within two months after having the one-year follow-up CA. CLINICAL RELEVANCE: This study will determine if 64-slice MSCT can offer equivalent graft patency information in asymptomatic post-CABG patients when compared to the "gold standard" CA, with less risk and at a lower cost.